HIGHLIGHTS
- who: Zeta Chow and collaborators from the Department of Surgery, University of Kentucky, Lexington, KY, USA have published the research work: PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine Tumors, in the Journal: Cells 2021, 10, x FOR PEER REVIEW of /2021/
- what: The aim of this study was to examine a new treatment strategy by combining PI3K/mTOR inhibition and radiotherapy. The authors evaluated the response of GEP-NET_cells to the combination of a novel PI3K/mTOR inhibitor in conjunction with radiotherapy. Since complete 8 of 17 Akt . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.